Stock DVA DAVITA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings DaVita Inc.

Equities

DVA

US23918K1088

Real-time Estimate Cboe BZX
Other stock markets
 03:31:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
128.5 USD +1.86% Intraday chart for DaVita Inc. -1.69% +22.39%
Apr. 10 Davita Announces Dennis Pullin to Its Board of Directors CI
Mar. 13 Transcript : DaVita Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
  • According to Refinitiv, the company's ESG score for its industry is good.

Strengths

  • The company has a low valuation given the cash flows generated by its activity.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Sales forecast by analysts have been recently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
DAVITA INC. Stock DaVita Inc.
+22.39% 11.06B
B-
CVS HEALTH CORPORATION Stock CVS Health Corporation
-11.76% 87.46B
B-
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+12.84% 78.56B
C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+10.85% 29.37B
C+
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-11.70% 16.78B
B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-4.17% 16.01B
A-
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-7.22% 13.98B
A-
EUROFINS SCIENTIFIC SE Stock Eurofins Scientific SE
+0.92% 12.31B
A-
PURE HEALTH HOLDING Stock Pure Health Holding
-30.35% 12.07B - -
SOLVENTUM CORPORATION Stock Solventum Corporation
0.00% 11.06B - -
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. DVA Stock
  4. Ratings DaVita Inc.